SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma
SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma
复制标题
DOI：
10.1111/j.1749-6632.2012.06772.x
复制
发表时间：
2012-01-01
期刊：
影响因子：
--
通讯作者：
Titulaer, Maarten J.
中科院分区：
文献类型：
--
作者：
Lipka, Alexander F.;Verschuuren, Jan J. G. M.;Titulaer, Maarten J.
Lambert-Eaton肌无力综合征（LEMS）是一种神经肌肉突触的自身免疫性疾病。大约一半的LEMS患者患有相关的小细胞肺癌（SCLC），通常在诊断LEMS后检测到。这篇简短的综述总结了临床和血清学标记物显示，预测LEMS患者中存在小细胞肺癌。SOX 1抗体是SCLC-LEMS的特异性标志物，但它们也在没有副肿瘤神经综合征的SCLC患者中发现。未发现SOX 1阳性患者的任何临床特征或生存影响。一些临床标志物也区分SCLC-LEMS和非肿瘤LEMS。对来自两个独立患者队列的这些临床和人口统计学特征的详细分析导致了DELTA-P评分的开发。该预测模型提供了一种简单的临床工具，以指示疾病早期SCLC的存在。DELTA-P评分可用于指导个体患者的肿瘤筛查。
Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder of the neuromuscular synapse. About half of LEMS patients have an associated small cell lung carcinoma (SCLC), which is usually detected after diagnosis of LEMS. This short review summarizes clinical and serological markers shown to predict the presence of SCLC in LEMS patients. SOX1 antibodies are a specific marker for SCLC-LEMS but they are also found in SCLC patients without paraneoplastic neurological syndromes. No relation to any clinical characteristic or survival effect has been found for SOX1-positive patients. Several clinical markers also discriminate between SCLC-LEMS and nontumor LEMS. Detailed analysis of these clinical and demographic characteristics from two independent patient cohorts has led to development of the DELTA-P score. This prediction model has provided for a simple clinical tool to indicate the presence of SCLC early in the course of the disease. The DELTA-P score can be used to guide tumor screening in individual patients.